Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Liabilities and Shareholders Equity (2021 - 2026)

Longeveron (LGVN) posted quarterly Liabilities and Shareholders Equity of $21.2 million for Q1 2026, up 1.74% year-over-year from $20.8 million in Q1 2025, and up 106.7% quarter-over-quarter from $10.3 million in Q4 2025.

Longeveron (LGVN) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends

Longeveron's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $21.2 million for Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity rose 1.74% year-over-year to $21.2 million; the TTM figure through Mar 2026 stood at $63.8 million (down 33.36% YoY), while the FY2025 annual figure was $10.3 million, down 59.85% from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 stood at $21.2 million, up from $10.3 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $29.9 million in Q3 2024, with the low at $9.7 million in Q1 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $18.2 million (2023), against an average of $18.5 million.
  • The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity surged 157.28% in 2024, then plunged 59.85% in 2025.
  • Longeveron's Liabilities and Shareholders Equity stood at $27.4 million in 2022, then slumped by 55.94% to $12.1 million in 2023, then surged by 111.61% to $25.6 million in 2024, then slumped by 59.85% to $10.3 million in 2025, then soared by 106.7% to $21.2 million in 2026.
  • Business Quant data shows LGVN's Liabilities and Shareholders Equity at $21.2 million in Q1 2026, $10.3 million in Q4 2025, and $15.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 10.96 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 9.18 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 5.56 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 25.60 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 2.10 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 19.82 Bn
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00 15.49 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 15.49 Mn
Mar 31, 2026 21.21 Mn
Dec 31, 2025 10.26 Mn
Sep 30, 2025 15.56 Mn
Jun 30, 2025 16.75 Mn
Mar 31, 2025 20.85 Mn
Dec 31, 2024 25.56 Mn
Sep 30, 2024 29.91 Mn
Jun 30, 2024 19.39 Mn
Mar 31, 2024 9.70 Mn
Dec 31, 2023 12.08 Mn
Sep 30, 2023 11.63 Mn
Jun 30, 2023 17.09 Mn
Mar 31, 2023 21.81 Mn
Dec 31, 2022 27.41 Mn
Dec 31, 2021 42.77 Mn